| |
EGPA
|
GPA
|
MPA/RLV
|
Unclassifiable
|
|---|
|
(n = 14)
|
(n = 33)
|
(n = 78)
|
(n = 31)
|
|---|
|
Male/female
|
5/9
|
12/21
|
35/43
|
9/22
|
|
Mean (median) age (years)a,c
|
58.0 ± 16.9 (62)
|
63.6 ± 12.6 (61)
|
71.1 ± 10.0 (73)
|
70.6 ± 11.8 (73)
|
|
MPO-ANCAa,c
|
7 (50.0)
|
18 (54.6)
|
76 (97.4)
|
29 (93.5)
|
|
PR3-ANCAb,c
|
0 (0)
|
15 (45.5)
|
2 (2.6)
|
1 (3.2)
|
|
ANCA-negativea,b
|
7 (50.0)
|
3 (9.1)
|
1 (1.3)
|
2 (6.5)
|
|
Serum creatinine (mg/dl)a
|
0.71 ± 0.39
|
1.51 ± 1.32
|
2.46 ± 2.18
|
0.69 ± 0.23
|
|
Disease severityc
|
|
Localised
|
0 (0)
|
4 (12.1)
|
0 (0)
|
0 (0)
|
|
Early systemic
|
1 (7.1)
|
5 (15.1)
|
15 (19.2)
|
15 (48.4)
|
|
Generalised
|
13 (92.9)
|
18 (54.6)
|
47 (60.3)
|
13 (41.9)
|
|
Severe
|
0 (0)
|
6 (18.2)
|
16 (20.5)
|
3 (9.7)
|
|
General performanced
|
|
0/1/2/3/4
|
1/7/2/4/0
|
8/11/2/11/1
|
10/29/17/16/6
|
3/11/7/9/1
|
|
Nongranulomatous pulmonary involvement
|
|
Interstitial lung diseasea
|
2 (14.3)
|
3 (9.0)
|
37 (47.4)
|
19 (61.3)
|
|
Alveolar haemorrhage
|
0 (0)
|
2 (6.1)
|
9 (11.5)
|
2 (6.5)
|
- Values expressed as mean ± standard deviation or number (percentage) unless otherwise noted. AAV, antineutrophil cytoplasmic antibody-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; EGPA, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); GPA, granulomatosis with polyangiitis (Wegener’s granulomatosis); MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase-3; RLV, renal-limited vasculitis. Comparisons between the EGPA, GPA, and MPV/RLV groups were made by Student t test or Mann–Whitney U test. Statistical significance was determined by P < 0.05/3 using Bonferroni correction: aEGPA versus MPA/RLV, bEGPA versus GPA, cGPA versus MPA/RLV. Unclassifiable AAV was not compared with other forms of AAV. dGeneral performance was categorised according to the World Health Organization performance status except category 5 (death).
